Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06669571 in Idiopathic Parkinson's Disease
NCT02565628Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing PF-06669571 with Placebo (2 arms). Primary endpoints: Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III at Day 7, Columbia Classification Algorithm of Suicide Assessment Category and 5 more. Started Nov 2015; status: completed.
02
Drugs
PF-06669571
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02565628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565628.